Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
04:43pm, Sunday, 08'th Mar 2026
NEW YORK, March 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and Janua
NEW YORK, March 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and Jan
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026
08:27am, Sunday, 08'th Mar 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquir
New York, New York--(Newsfile Corp. - March 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2
New York, New York--(Newsfile Corp. - March 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2
FDA reversals leave investors worrying about the fates of other experimental drugs
11:33am, Friday, 06'th Mar 2026
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:50am, Friday, 06'th Mar 2026
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio”
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquir
REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
05:45pm, Thursday, 05'th Mar 2026
REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors a
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and Jan
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST
02:25pm, Thursday, 05'th Mar 2026
Promise vs. Reality: The REGENXBIO Gene Therapy Performance Gap NEW YORK, March 5, 2026 /PRNewswire/ -- "Very promising results.
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
09:25am, Thursday, 05'th Mar 2026
Regenxbio (RGNX) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $1.01 per share a year ago.
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
07:05am, Thursday, 05'th Mar 2026
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected earl
REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX
09:00am, Wednesday, 04'th Mar 2026
NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit. CLASS DEFINITION
